por
Thomas Dworetzky, Contributing Reporter | April 13, 2017
The deal closed in March,
at which time Steve MacMillan, Hologic's Chairman, President and Chief Executive Officer, stated, "acquiring Cynosure, combined with divesting our blood screening business, fundamentally reshapes our business portfolio and makes us a stronger, faster-growing company.”
Cynosure, which has over 20 products for noninvasive body contouring, hair removal, skin revitalization and women's health, recently launched the world's first FDA-cleared laser treatment for noninvasive body contouring, SculpSure. It also owns a carbon-dioxide laser for women's health called MonaLisa Touch.
About 60 percent of the company's business comes from physicians outside the traditional areas of plastic surgery and dermatology, with a significant focus on OB/GYN applications.
The aesthetics segment is not "subject to reimbursement risks, making it less cyclical," Margaret Kaczor, analyst at William Blair, told Reuters.
"Larger acquirers can access a fast-growing, profitable market that is just in the first quarter of the game," she added.
Back to HCB News
